SignatureFD’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$238K Buy
4,249
+913
+27% +$47.5K ﹤0.01% 1005
2026
Q1
$160K Buy
3,336
+58
+2% +$2.54K ﹤0.01% 1115
2025
Q4
$127K Buy
3,278
+182
+6% +$6.94K ﹤0.01% 1203
2025
Q3
$109K Sell
3,096
-62
-2% -$2.25K ﹤0.01% 1250
2025
Q2
$114K Buy
3,158
+464
+17% +$15.4K ﹤0.01% 1184
2025
Q1
$83.9K Buy
2,694
+123
+5% +$3.9K ﹤0.01% 1309
2024
Q4
$65.6K Sell
2,571
-1,283
-33% -$34K ﹤0.01% 1430
2024
Q3
$109K Sell
3,854
-1,840
-32% -$51K ﹤0.01% 1177
2024
Q2
$150K Sell
5,694
-4,920
-46% -$136K ﹤0.01% 961
2024
Q1
$322K Sell
10,614
-272
-2% -$8.02K 0.01% 656
2023
Q4
$306K Buy
10,886
+5,007
+85% +$138K 0.01% 636
2023
Q3
$160K Buy
5,879
+4,335
+281% +$129K ﹤0.01% 823
2023
Q2
$47.5K Sell
1,544
-686
-31% -$23.2K ﹤0.01% 1465
2023
Q1
$80.3K Buy
2,230
+1,699
+320% +$63K ﹤0.01% 1150
2022
Q4
$21K Sell
531
-39
-7% -$1.63K ﹤0.01% 1779
2022
Q3
$23K Buy
570
+131
+30% +$5.59K ﹤0.01% 1678
2022
Q2
$18K Sell
439
-249
-36% -$10.2K ﹤0.01% 1836
2022
Q1
$27K Buy
688
+241
+54% +$9.46K ﹤0.01% 1696
2021
Q4
$18K Buy
447
+377
+539% +$14.6K ﹤0.01% 1838
2021
Q3
$3K Buy
70
+18
+35% +$700 ﹤0.01% 2551
2021
Q2
$2K Buy
52
+5
+11% +$213 ﹤0.01% 2613
2021
Q1
$2K Buy
47
+34
+262% +$1.61K ﹤0.01% 2522
2020
Q4
$1K Buy
+13
New +$552 ﹤0.01% 2475

Other funds holding RPRX

SignatureFD's RPRX Position: Q2 2026 in Review

SignatureFD increased its Royalty Pharma (RPRX) stake by 27% in Q2 2026, buying an estimated $47.5K and bringing the position to 4,249 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

SignatureFD first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $322K in Q1 2024. 107 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • SignatureFD held 4,249 shares of Royalty Pharma worth $238K as of Q2 2026.
  • SignatureFD bought 913 Royalty Pharma shares in Q2 2026, an estimated $47.5K.
  • Royalty Pharma made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1005 holding.
  • SignatureFD first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • SignatureFD's Royalty Pharma position peaked at $322K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.